4.4 Article

The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours

期刊

ACTA ONCOLOGICA
卷 60, 期 12, 页码 1597-1603

出版社

TAYLOR & FRANCIS LTD
DOI: 10.1080/0284186X.2021.1978540

关键词

Low muscle mass; immune checkpoint inhibitors; immunotherapy; immune-related severe toxicity

类别

向作者/读者索取更多资源

Research shows that there is no significant difference in clinical outcomes and safety between patients with low muscle mass and those with non-low muscle mass treated with ICIs.
Background Evidence suggests that sarcopenia is a significant predictive factor of worst outcomes and treatment-associated toxicities in patients with metastatic solid tumours. The aim of this study was to explore the relationship between low muscle mass and clinical outcomes and immune-related severe toxicities (IrST) in patients treated with immune checkpoint inhibitors (ICIs). Methods A retrospective cohort of 261 consecutive metastatic solid tumour patients treated with ICIs were included in our study. Low muscle mass was defined as skeletal muscle index <41 cm(2)/m(2) for females and <43 cm(2)/m(2) for males if body mass index (BMI) <25 kg/m(2) or <53 cm(2)/m(2) if BMI >= 25 kg/m(2). Severe toxicities (ST), including grade III-IV toxicities and side effects leading to treatment interruption, were recorded. Results The majority of patients (n = 179; 69%) included in this study had metastatic lung cancer. The prevalence of low muscle mass was 47%. The median progression-free survival (PFS) was 32.2 weeks for low muscle mass patients and 24.3 weeks for non-low muscle mass patients (adjusted HR, 0.80; 95% CI, 0.60-1.055; p = 0.11). For low muscle mass and non-low muscle mass lung cancer patients, median PFS was 24.0 weeks and 18.8 weeks (adjusted HR, 0.70; 95% CI, 0.50-0.98; p = 0.04) and median overall survival was 50.7 weeks and 41.1 weeks (adjusted HR, 0.77; 95% CI, 0.54-1.10, p = 0.15) respectively. Immune-related severe toxicities occurred in 3.3% and 9.4% of low muscle mass and non-low muscle mass patients respectively (adjusted OR, 0.69; 95% CI: 0.31-1.49; p = 0.35). Conclusion No difference in outcomes and safety was observed for low muscle mass and non-low muscle mass patients treated with ICIs.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据